This experiment aims to develop and validate 4R-tau targeting therapies specifically for Progressive Supranuclear Palsy (PSP) and Corticobasal Syndrome (CBS), the two major 4R-tauopathies. Unlike Alzheimer's disease which involves all six tau isoforms, PSP and CBS are characterized by preferential aggregation of 4R-tau, making isoform-selective targeting a promising therapeutic strategy.
Primary Hypothesis: Selective inhibition of 4R-tau aggregation will reduce tau pathology and improve motor and cognitive outcomes in PSP/CBS mouse models.
Secondary Hypothesis: Combination of 4R-tau aggregation inhibitors with microtubule-stabilizing agents will show synergistic neuroprotective effects.
Progressive Supranuclear Palsy and Corticobasal Syndrome are two clinically and pathologically distinct 4R-tauopathies. Key features include:
Previous anti-tau immunotherapy trials (gosuranemab, tilavonemab) failed in PSP, highlighting the need for:
| Item | Supplier | Cost (USD) |
|---|---|---|
| 4R-tau aggregation inhibitor (lead compound TBD) | Custom synthesis | $120,000 |
| 4R-tau specific antibody (TBI-1 or similar) | Invitrogen | $8,000 |
| 3R/4R tau isoform-specific antibodies | Sigma-Aldrich | $6,000 |
| AT8 antibody | Thermo Fisher | $500 |
| GFAP antibody | Dako | $350 |
| Iba1 antibody | Wako | $400 |
| 4R-tau PET tracer (PI-2620 or novel) | Avid Radiopharmaceuticals | $200,000 |
| PET/CT scanner time | In-house | $50,000 |
| Behavioral apparatus | Stoelting | $25,000 |
| Stereotaxic surgery equipment | Harvard Apparatus | $15,000 |
Estimated Total Cost: $425,000
Total Duration: 24 months
| Dimension | Score (1-10) | Rationale |
|---|---|---|
| Scientific Value | 10 | First comprehensive 4R-tau specific therapy validation |
| Feasibility | 7 | Requires new compound development, but models exist |
| Novelty | 10 | Novel isoform-selective approach, not attempted in clinical trials |
| Disease Impact | 10 | Addresses critical unmet need for PSP/CBS (no approved therapies) |
| Reach | 8 | Applicable to ~50,000 PSP and ~10,000 CBS patients in US |
| Cost Efficiency | 6 | High cost due to PET imaging and specialized reagents |
| Time Efficiency | 6 | 24-month timeline is lengthy but necessary |
| Evidence Base | 8 | Strong preclinical data on 4R-tau biology |
| Addresses Uncertainty | 9 | Tests critical hypothesis about isoform-specific therapy |
| Translation Potential | 9 | Clear path to clinical trial if preclinical results positive |
Total Score: 83 × weight normalization = ~118/140